⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27278396 | 0.84 | HTT (0.67) | — | |
| SCHEMBL892658 | 0.80 | — | — | |
| SCHEMBL15836938 | 0.80 | — | — | |
| Lithium Ion SCHEMBL30968154 | 0.78 | HTT (0.51) | — | |
| SCHEMBL17813609 | 0.77 | — | — | |
| SCHEMBL17881863 | 0.77 | — | — | |
| SCHEMBL4166588 | 0.77 | HTT (0.50) | — | |
| SCHEMBL5531898 | 0.77 | SMN1; SMN2 (0.58) | — | |
| SCHEMBL16865849 | 0.77 | KMT2A (0.51) | — | |
| SCHEMBL2625471 | 0.77 | HTT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-10 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468437-B2 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| CN-100415744-C | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| WO-2007044296-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK & CO., INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043015-A1 | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| CN-1823064-A | 2-arylamino-pyrimidines for the treatment of GSK 3-related disorders | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | CN | disclosed |
| CN-1174981-C | Imidazo [1, 2-A ] pyridine and pyrazolo [2, 3-A ] pyridine derivatives | — | 2004-11-10 | — | — | CN | disclosed |
| CN-1370163-A | Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | CN | disclosed |